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ABSTRACT
Transport and Utilization of Arginine and ArginineContaining Peptides by Rat Alveolar Macrophages
Xiaodong Yang
Purpose. To demonstrate that alveolar macrophages (AM) from
rats exhibit pepT1-like transporter for the uptake of small
arginine-containing peptides (ACPs) and utilized these
peptides as direct substrates for nitric oxide (NO)
production.
Method. A HPLC assay was developed for quantitative
measurement of Arg and ACPs in rat plasma and
bronchoalveolar lavage (BAL) fluid. The uptake of small
peptides by rat AM was evaluated using fluorescein
isothiocynate (FITC)-labeled (*) peptides (Arg-Lys*, β-AlaLys*, and Gly-Sar-Lys*), HPLC analysis of potential peptide
degradation, and known inhibitors on arginine (Arg) and
PepT1 transport. NO production by AM through Arg and ACPs
was studied with and without inhibition by transport
inhibitors. The presence of PepT1-like transporter on AM
was evaluated using antipepT1 antisera and Western blot
analysis. The substrate specificity of Arg-Gly and Arg-GlyAsp was determined using purified inducible nitric oxide
synthase (iNOS). The availability of ACPs in the lung was
determined by the HPLC analysis of plasma and (BAL) fluid.
Results. The FITC-labeled peptides were internalized by AM
without degradation. Uptake of Arg-Lys*, β-Ala-Lys*, and
Gly-Sar* was blocked (~50%) by cephradine, but not by Lys
(an inhibitor on CAT-2B for arginine transport). The NO
production by AM through ACPs was significantly blocked by
PepT1 inhibitors and by an antiPepT1 antibody in a dosedependent manner. These inhibitors had no effect on AM
production of NO using Arg as a substrate. Arg-Gly and ArgGly-Asp were found to be direct substrates for iNOS with
similar Km and Vmax values to those of Arg. But the
production of NO by AM using ACPs as substrate was 2-fold
higher than using Arg as a substrate. Both Arg-Gly and ArgGly-Asp were found in rat plasma and BAL fluid. The
presence of a PepT1-like transporter on AM was confirmed by
Western blot.

Conclusion. This study shows that AM exhibits PepT1-like
transporter for small peptide uptake. ACPs, through PepT1like transporter, can serve as direct substrates for AM
production of NO, an important mediator on both protection
the lung from bacteria infection and augments inflammation
lung injury.
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Chapter I

Statement of Question, Hypothesis, and Specific Aims of This
Study

Peptide transporters play a pivotal role in efficient
absorption of protein digestion products (mainly di- or
tri-peptides) through plasma membranes in the small
intestine.

As a result of the transport of these small

peptides, up to 78% of the amino acids in the plasma are in
the form of di- or tri-peptide in experimental animals
(Seal and Parker 1991).

Removal of such large amounts of

small peptides from the plasma into an organ could be the
result of dipeptide hydrolysis in plasma or of actual
utilization of peptides by the organ.

Lochs et al. (1988)

showed that the hydrolysis in plasma was not a major
mechanism for the disappearance of dipeptides from
circulation.

This suggests that direct utilization of

these peptides could occur in various tissues.

Indeed, direct utilization of small peptides by
different tissues has been reported (Krzysik and Adibi,
1977; McCormick and Webb, 1982).

Fei et al. (1994)

reported that small peptides might be directly used by the
liver, kidney, brain and placenta.

More recently, Wang et

al (1996), for example, reported that di- or trimethionine-containing peptides were more efficiently
utilized than free methionine in the synthesis of mammary
tissue proteins secreted from lactating mice.

1
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utilization of small peptides in anabolic process in other
tissues, including the lung remains unclear.

In pulmonary host defense, nitric oxide (NO) is
produced in particularly large amounts by alveolar
macrophages (AM) to provide cytostatic/cytotoxic effects
against invading bacteria.

Induction of NO production by

AM and agents such as lipopolysaccharide (LPS), depends not
only on the activity of the inducible nitric oxide synthase
(iNOS), but also on the availability of the substrate
arginine.

Recent studies have shown that arginine is taken

up by AM through the cationic amino acid transporter 2B
(CAT-2B) (Caivano, 1998).

LPS, which stimulates the

production of iNOS, also facilitates AM uptake of arginine
(Kakuda et al., 1999).

The substrate for NO synthesis may not be necessarily
restricted to arginine.

Thiemermann et al. (1991) reported

that in endothelial cells, arginine-containing dipeptides
fit the active site of NO synthase than arginine in
endothelial cells.

In addition, Meredith and Boyd (1995)

reported the presence of a peptide transport protein in the
pulmonary type II cells and suggested that this transporter
may play a role in lung peptide homeostasis.

Recently

Groneberg et al. (2001) demonstrated the presence of a
peptide transporter in alveolar type II pneumocytes,
bronchial epithelium, and endothelium of small vessels of
mammalian lungs.

Due to the availability of small peptides

in plasma and the presence of peptide transporter in the

2
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alveolar epithelium and endothelium, direct utilization of
these small peptides is therefore feasible.

The hypothesis of this study was that alveolar
macrophages can take up arginine-containing peptides and
directly utilize them as substrates for NO production, and
that this process is regulated by a peptide transporter.

A number of transporters including PepT1 and PepT2
located in the intestinal and kidney epithelial cells,
respectively, have been identified for di- or tri-peptide
transport (Fei et al., 1994, Saito et al. 1996).

It is

reasonable to suggest that in various organ systems, where
transport or absorption of small peptide is necessary,
there are similar peptide transporters.

In order to characterize the potential presence of a
peptide transporter on AM, this research used the structure
of PepT1 (Figure 1) as a model to test the underlying
hypothesis.

In this approach, two peptide segments,

peptide I and peptide II (figure 1-3), while exhibit high
homology in amino acid sequence among rat, rabbit, and
human PepT1, were chosen to produce the anti-PepT1
antisera, and used as proteins for the detection of a
peptide transporter on AM.

The specific aims of this study were:
(1)

To develop a reliable method for the analysis of
arginine and arginine-containing peptides in the
biological system,

3
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(2)

To establish that appreciable amount of argininecontaining small peptides are present in the lungs

(3)

To demonstrate the presence of a peptide transporter
in alveolar macrophages (AM) and the uptake of
arginine-containing peptides through this transporter,
and

(4)

To determine the arginine-containing peptides are
direct substrates for the inducible nitric oxide
synthase (iNOS) in AM for NO production.

The outcome of this research should provide a
plausible mechanism for the role of arginine-containing
peptides in vivo NO production.

4
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Chapter II

Review of Literature

1. Peptide Transporters

The existence of a peptide transporter in human small
intestine was hypothesized more than 25 years ago (Matthews
and Adibi, 1976).

Due to the technical difficulty, this

transporter protein was not identified until recent years.
The first peptide transporter, called (PepT1) was cloned by
Fei et al. (1994) from rabbit small intestine.

The second

one, called PepT2, was cloned from absorptive cells of the
renal proximal tubule (Saito et al., 1996).

The discovery

of peptide transporters not only supported the hypothesis
but also provided a useful tool for studying the
utilization of peptides by various tissues.

1.1. Physiological Importance

1.1.1. Peptide Transporter in the Small Intestine

The physiological importance of a small peptide
transporter became apparent with the observation of small
peptides in the gut lumen, then their disappearance from
small intestine, and reappearance in portal vein after a
protein meal.

Adibi et al. (1971 and 1981) investigated

whether intact absorption played a role in the small
peptide disappearance.

A series of small peptides were

infused directly into the upper small intestine of human

5
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volunteers and their fates were determined.

The results of

these studies suggested the absorption of large amount
dipeptides and tripeptides in an intact form.

This observation challenged the traditional idea that
dietary proteins must be broken down to amino acids in the
gut lumen before absorption could occur.

The importance of

peptide transporter was further confirmed by the fact of
patients with genetic impairments of amino acid absorption
(Cystinuria and Hartnup diseases).

These impaired

individuals do not experience protein malnutrition.

Cystinuria patients lack the basic amino acid
transporter and can not absorb arginine from their
intestine.

However, the dipeptide Arg-Leu is well absorbed

in these patients.

Hartnup disease is a hereditary

condition in which the active transport of several neutral
amino aids is deficient from both renal tubules and the
small intestine.

It exhibits a pellagra-like syndrome, but

is benign, and patients fare quite well nutritionally by
absorbing small peptides.

This would not have been

expected if the amino acid transporters, instead of the
peptide transporters, were mainly responsible for
absorption of protein digestion products.

1.1.2. Peptide Transporter in Kidney

In addition to the PepT1 in small intestine, a peptide
transporter (PepT2), is also present in absorptive cells of
the renal proximal tubule (Saito et al., 1996).

6
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transporter via the active transport process plays a
significant role in conserving peptide bound amino nitrogen
which might otherwise be lost in the urine.

Such a physiologically significant role, however, was
not readily accepted because it was generally assumed that
the concentrations of small peptides in the circulation
were very low.

However, recent studies (Gardner, 1994,

Matthews 1994, Schlagheck and Webb, 1984, Seal and Parker,
1991) have provided clear evidence that up to 70% of the
plasma amino acid pool is in the peptide-bound form.

1.2. Regulation of Peptide Transporter

The knowledge on the regulation of peptide
transporters is limited.

The ability of the intestine to

absorb intact peptides varies with age.

In several animal

species including man, the peptide transport system is
established in the small intestine prior to birth
(Guandalini and Rubino, 1982, Himukai et al., 1980, Sagawa
et al., 1979).

The peptide absorptive capacity is maximal

at birth and then decreases with age to reach adult levels.

The intestinal peptide transport system is also
regulated by diet. A high-protein diet enhances the ability
of the intestine to absorb peptides. A switch from a lowto a high-protein diet resulted in a 1.5-2 fold increase in
the pepT1 mRNA level in rat intestine (Ferraris et al.,
1988).

Vazquez et al. (1985) showed that metabolic

perturbations, such as starvation, alter peptide transport

7
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in the jejunum of human volunteers. Short-term restriction
of diet, for example, increases the intestinal peptide
transport activity.

However, the mechanism that might

regulate this transporter was not studied.

Our present knowledge of the regulation of the
intestinal peptide transport system by hormones is limited.
Little is known about the regulation of the peptide
transport in the kidney.

The principal peptide transporter

expressed in the kidney through the action of hormones
and/or second messengers has not been studied.

1.3. Therapeutic Application

1.3.1. Pharmacological Importance
The peptide transport systems present in the small
intestine and the kidney also have pharmacological
relevance.

Many orally active peptide-like drugs possess

structural features similar to those of the physiologic
substrates of the peptide transport system.

The intestinal

peptide transport system recognizes these peptide-like
drugs (e.g. β-lactam antibiotics) as substrates and acts as
a vehicle for their effective absorption (Okano et al.,
1986).

The peptide transport system in the kidney is
responsible for active reabsorption of these antibiotics
from the glomerular filtrate and, hence, increases their
half-life in the circulation.

Thus, the intestinal and

8
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renal peptide transport systems play an important
pharmacologic role in determining the efficiency of these
antibiotics.

It is obvious that the peptide antibiotics are not the
only pharmacologically relevant compounds that use the
peptide transport system as a vehicle for cellular uptake.
The transport system also participates in the transport of
many other therapeutically and biologically active
peptides, such as angiotensin-converting enzyme inhibitors,
renin inhibitors, and anticancer drugs (Inui et al., 1992).

1.3.2. Clinical Importance

The peptide transport system in the small intestine
and the kidney has received increasing attention in recent
years.

In current clinical practice, short-chain peptides

are being seriously considered as viable substitutes for
free amino acids in enteral and parenteral solutions.

The

reason for that is that since the transport of peptides in
the small intestine is the primary mode of nitrogen
absorption, it is logical to employ all peptides instead of
free amino acids as the source of nitrogen in enteral
solutions for patients.

Available evidence in laboratory animals and in man
strongly suggests that enteral solutions containing small
peptides may provide an absorptive advantage to patients
with severely reduced intestinal absorptive area and to
patients who are acutely cachectic (trauma, sepsis, and

9
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burns).

Moreover, synthetic di- and tri-peptides offer an

effective alternative means of amino acid delivery using
enteral solutions for those amino acids that are unstable
or sparingly soluble in free form (e.g. tyrosine, cystine,
glutamine).

Expanded knowledge about extraintestinal peptide
assimilation in animals, especially the extraordinary
ability of the mammalian kidney to extract small peptides,
is supporting the view that small peptides can be
substitute for free amino acids, not only in enteral
solutions, but also in parenteral solutions.

Recent

studies have shown that it is possible to supply daily
nitrogen requirements, intravenously, in the form of small
peptides to animals and man (Grimble et al., 1988,
Steinhardt et al., 1984).

The low osmolality of peptide-based parenteral
solutions is another advantage, especially in patients with
severe fluid restriction.

Furthermore, some free amino

acids, e.g. glutamine, are relatively unstable in solution
and during heat sterilization.

However, when included in

the form of a dipeptide, alanyl-glutamine (Ala-Gln), for
intravenous solutions, unlike free glutamine, is stable.
Human studies have shown that utilization of alanylglutamine is highly efficient and that the supplementation
of the parenteral solutions with this peptide significantly
reduces postoperative nitrogen losses and prevents the
post-operative reduction in muscle glutamine content
(Stehle et al., 1989).

10
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Thus, the peptide-based parenteral solutions may offer
a variety of advantages in a clinical setting, and the
basis for the clinical efficacy of these solutions is the
ability of extraintestinal tissues, primarily the kidneys,
to utilize peptides via the peptide transport.

In addition, the water solubility of some amino acids,
particularly tyrosine, is limited.

Water solubility of

tyrosine can be greatly increased by attachment of this
amino acid to a water-soluble amino acid in dipeptide form.
Therefore, mixtures of small peptides are used widely as
the nitrogen source for nutrition.

1.4. Tissue Distribution, Amino Acid Sequence, Antibody to
Peptide Transporters

PepT1 is expressed predominantly in epithelial cells
of the small intestine.

Rat PepT1 is a 710 amino acid

protein (rat) and is a highly conserved between species,
77% and 83%, with that of rabbit and human, respectively
(Miyamoto et al., 1996).

mRNA of PepT1 has been found in

other tissues including kidney, liver, brain, and pancreas
(Fei et al., 1994; Liang et al., 1995).

PepT2 is expressed predominantly in the kidney, and to
a small extent in the central nerve system and spleen.

It

is a 729 amino acid protein and showed 60-80%, and 83%
amino acid sequence identity with that of rabbit and human,
respectively.
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Both PepT1 and PepT2 share three common structural
features: (1) twelve α-helical transmembrane domains; (2)
one large extracellular loop that is positioned between
transmembrane domain 9 and 10; (3) intracellular location
of both N- and C- terminus amino acid.

Overall amino acid

identity is 48% between PepT1 and PepT2 in the rat.
Giacomini (1999) suggested that the extracellular loop
might play an important role in the interaction between
substrates and transporter.

Anti-peptide antibodies to transporters have been used
to identify and localize transporter protein (Saito et al.,
1995; Sai et al., 1996).

These anti-PepT1 antibodies

against synthetic peptides corresponding to the C-terminal
13-15 amino acids of the transporter were used in
immunoblotting and immunohistochemistry studies.

1.5. Peptide Transporter in Lung

The evidences for the presence of a peptide
transporter in lungs have increased.

Morimoto et al.

(1993) reported that dipeptides could be transported across
the alveolar epithelial cell monolayers.

Transport of

tripeptides in the lung has been investigated in detail
(Helliwell et al., 1994).

Meredith and Boyd (1995)

suggested that a proton-coupled peptide transport protein
is present in the apical surface of the pulmonary type II
cells, and that this transporter may play a role in lung
peptide homeostasis.
12
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Recently, a peptide transporter was reported to be
present in mammal lung cells, including alveolar type II
pneumocytes, bronchial epithelium, and endothelium of small
vessels (Groneberg et al., 2001).

The presence of the

peptide transporter in various cell types suggested that
direct utilization of peptides could occur also in the
lung.

2. Arginine and Arginine-Containing Peptides in Plasma and
Bronchoalveolar Lavage (BAL) Fluid

In our classical understanding of protein absorption,
we believe that dietary proteins are completely hydrolyzed
to free amino acids in the gut and that only free amino
acids can be transported by intestinal mucosa into the
circulation.

There is now substantial evidence that this

concept is not valid.

In fact, after a protein meal, most

amino acid constituents of proteins are not absorbed as
free amino acids but as dipeptides and tripeptides (Adibi
and Kim, 1981).

Webb (1986) reported that when comparing the
appearance of amino acids in portal plasma after a meal,
more than 70% were associated with the peptide amino acid
in experimental calves.

If these peptide amino acids are

of dietary origin, then this large contribution will be
significant.

Even if these peptide amino acids are not of

dietary protein origin, they present a large quantity of
amino acids with which other tissues in the animal must

13
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deal.

There is excellent agreement between Seal and Parker

(1991) and Gardner (1982, 1983) who reported that about 50%
peptide amino acids in rat and 65-78% in steer and sheep.

The distribution of the free amino acids arginine in
rat plasma and tissues has been reported (Barbul, 1990).
The concentration of arginine is 79-124 µM in plasma and
0.03-0.28 µmol/g in different tissues.

However, no

information is available about the distribution of
arginine-containing di- or tri-peptides in plasma and BAL
fluid.

3. Nitric Oxide, Arginine, and Arginine-Containing Peptides
Nitric oxide (NO) is an important signal transduction
mediator in a variety of physiological systems (reviewed in
Schmidt and Walter, 1994).

In pulmonary host defense, NO

is produced by alveolar macrophages (AM) in response to
inflammatory stimulation to provide cytotoxic effects
against invading bacteria (Beckerman et al. 1993), or to
regulate cellular cytokine secretion and cyclooxygenase
activity (Raso et al. 2001).

The induction of NO

production from AM, such as by lipopolysaccharide endotoxin
(LPS), depends not only on the activity of the inducible
nitric oxide synthase (iNOS), but also on the availability
of the substrate arginine.

NO synthesis from arginine is a reaction, which
involves two separate mono-oxygenation steps (Stuehr et
al., 1991).

Nω-Hydroxyarginine is an intermediate species

14
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formed by a reaction requiring one O2 and one NADPH and the
presence of tetrahydrobiopterin (BH4).

This reaction

appears to be similar to those carried out by the aromatic
amino acid hydroxylases, which also require BH4.

The second

step in the NO synthase reaction results in the oxidation
of Nω-Hydroxyarginine to form citrulline and NO.

Briefly

the production of NO can be described by following
formulae:
Arg + NADPH + H+ + O2 → HydroxyArg + NADP+ + H2O
HydroxyArg + 1/2 (NADPH + H2) + O2 → Cit + NO + H2O

Arginine as substrate for NO production has been
studied in detail (Barbul, 1990).

However, little is known

whether or not arginine is the only substrate.

Thiemermann

et al. (1991) showed that Arg-Phe fits the active site of
endothelial cell NOS than arginine and that this peptide is
not degraded to free amino acid during the reaction.

This

suggested that the substrate specificity of the NOS in
endothelial cells is not necessarily restricted to L-Arg.

4. Uptake of Arginine, Arginine-Containing Peptides by
Alveolar Macrophages for NO Production
System y+ is widely believed to be the major carrier of
cationic amino acids in adult tissues (Malandro and
killberg, 1996).

Arginine is transported across cell

membranes by system y+ which is Na+ independent and pH
insensitive (White et al., 1982).
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Three cationic amino acid transporters have been
identified termed CAT-1, CAT-2, and CAT-2B.
2B are present in macrophages and monocytes.

CAT-1 and CATIn RAW264

macrophages, CAT-1 is accounted for the basal rate of
arginine uptake, while CAT-2B, induced by the
lipopolysaccharide (LPS), a component of the bacterial cell
wall, is responsible for the increased rate of arginine
uptake.

The uptake of arginine can be competitively

blocked by cationic amino acid e.g. lysine (Bogle et al.
1992).

The importance of CAT transporters and arginine uptake
for the production of NO in AM is well documented, however,
whether arginine-containing peptides can be taken up as
direct substrates for NO production remains to be
determined.

5. Nitric Oxide Synthases (NOS)

Nitric oxide is produced from arginine by nitric oxide
synthase (NOS).

NOS was first described in 1989 (Knowles

et al., 1989), first purified in 1990 (Bredt and Snyder,
1990), and first cloned in 1991 (Bredt et al., 1991).
There are three NOS isoforms have been identified in
mammalian cells to date.

Type I NOS (nNOS, originally

identified as a constitutive protein in neuronal tissue)
and type III NOS (eNOS, originally identified as
constitutive in vascular endothelial cells) are calciumdependent enzymes that are expressed in a cell-specific
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manner and their activation produces the NO that mediates
most of the cGMP messenger functions of this molecule.

In

contrast, type II NOS (iNOS, originally identified as being
inducible by cytokines in macrophages and hepatocytes) has
an ubiquitous tissue distribution and is only expressed
during cell-mediated immune responses.

For this reason it

is usually referred to as inducible NOS (iNOS).

The iNOS

in macrophages is only found to be expressed after
induction with LPS or cytokines.

The half-saturating

concentration (Km) of the substrate L-arginine measured in
vitro for iNOS is about 30 µM (Closs et al., 2000).
6. Measurement of NO

In general,

two techniques have been commonly used as

the basis for the measurement of NO, the oxidation of
hemoglobin and the formation of NO2- + NO3-.
NO rapidly reacts with oxyhemoglobin to form NO3- and
met-hemoglobin.

The resulting spectral changes have been

used as the basis of a spectrophotometric assay of NO
synthase (Knowles et al., 1990).

With dual wavelength

measurement at 401 and 421 nm this method has a sensitivity
of less than 20nM.
Formation of NO2- + NO3-, the oxygenation products of NO
can be measured by a variety of techniques.

One of them

uses reduction of NO3- to NO2- by nitrate reductase or
metallic catalysts followed by the colorimetric Griess
reaction (Stuehr et al., 1989).
17
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7. Inhibition of NO Synthase

The study of NO synthesis in mammalian systems has been
greatly facilitated by the identification of competitive
inhibitors of NO synthase.

N-Monomethyl-L-arginine (L-NMMA)

is one of the most commonly used.

L-NMMA has been shown to

be a competitive inhibitor (competitive with L-arginine) of
all the form of NOS so far examined, with an IC50 of ~7.4 µM
for iNOS (Stuehr et al. 1989).

A range of arginine analogs

has been found to inhibit NO synthases.

Like L-NMMA, these

compounds are competitive inhibitors.

Another way of inhibiting NO synthase in biological
systems is to limit the supply of one of its substrates or
cofactors.

This type of indirect inhibition has been

demonstrated using inhibitors (N-acetyl-5-hydroxytryptamine)
of tetrahydrobiopterin (BH4) synthesis.

Because of the

turnover of BH4 in intact cells and tissues, inhibition of
its synthesis eventually results in deletion of BH4 to
concentrations that limit NO synthesis.

NOS has been demonstrated to be subject to feedback
inhibition by NO: two forms of NOS, brain constitutive nNOS
and macrophage inducible iNOS were shown to be inhibited by
NO either produced by the enzyme itself or generated from
chemical NO donors (Stuehr and Griffith, 1992).

It is

likely that this inhibition results form interaction with
the heme of NO synthase.
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8. Remaining Questions about the Peptide Transporters

A number of issues regarding the peptide transporters
still remain to be investigated.
(1) Are there additional H+/peptide transporters other
than PepT1 and PepT2? What is the functional relationship,
if any, between these transporters?
(2) Is the H+/peptide cotransporter system is expressed
in the plasma membrane of mammalian tissues other than the
intestine and kidney?

Northern blot analysis reveals the presence of mRNA
transcripts that hybridize to the PepT1 cDNA probe in
liver, brain, and pancreas.

However, no information is

available on H+-couple peptide transport in these organs,
whether the mRNA transcripts code for peptide transporters
or for different transporters with homology to the peptide
transporters remains to been investigated.
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Materials and Methods

1. Materials

Male Sprague-Dawley rats weighing 200-250 g (Hilltop
Labs.

Scottsdale, PA) were used as a source for alveolar

macrophages (AM) throughout this studies.

E.Coli

lipopolysaccharide (LPS), arginine (Arg), Arg-Sar, Arg-Gly,
Arg-Lys, Arg-Gly-Asp, cephradine, and cephalexin were
obtained from Sigma Co (St. Louis, MO).

Fluorescein

isothiocynate (FITC)-labeled lysine (Lys*) and lysinecontaining peptides (β-Ala-Lys*, Arg-Lys*, and Gly-Sar-Lys*)
were purchased from Genemed Synthesis, Inc (San Francisco,
CA).

In order to probe the presence of pepT1-like

transporter on AM, two peptide segments (Peptide I and
Peptide II) corresponding to P457-471 (PGHRHTLLVWGPNLY) and
P480-494 (QKPEKGENGIRFVST) of the extracellular domain of
rat pepT1 (Miyamoto, 1996) were synthesized and their antirabbit anti-sera [anti-p457-471 antiserum (antiserum I) and
anti-p480-494 antiserum (antiserum II)] were developed
commercially by Genemed Synthesis, Inc.

Peptides I and II

represent two sections of the extracellular domain that
show the highest degree of amino acid sequence homologous
among rat, rabbit, and human pepT1.

Peptide II exhibits

relatively higher hydrophilicity than Peptide I due to the
presence of more charged amino acid residues (K, lysine; R,
arginine; E glutamate).

Purified iNOs was obtained from

CalbioChem (San Francisco, CA). Rat pepT1 protein was
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kindly received from Dr. You-jun Fei (Department of
Biochemistry, University of Georgia) as a gift.

All other

reagents were purchased from Sigma Co. (St. Louis, MO).

2. Methods

2.1. Plasma Sample Preparation

Male Sprague-Dawley rats (~ 250 g) were anesthetized
with sodium pentobarbital (0.2 g/kg body weight).

seven ml

of blood was collected from the abdominal aorta and kept in
the heparinized ice-cold tubes. The blood samples were
spiked with 1 mM Arg-Sar as an internal standard for
subsequent HPLC analysis, centrifuged at 1500 x g at 4

0

C

for 10 min, and the plasma samples were collected. Two and
half ml of plasma were taken and boiled for 15 min
(deproteinization).

The treated plasma was centrifuged at

2000 x g at 40C for 30 min.

The supernatant was loaded on to a C18 cartridge (Vac
20, Waters) and the column was eluted with 30ml of 0.1% TFA
in methanol/water (95:1, pH2.4), then 30 ml of water
containing 30% methanol (pH 2.4), and 10 ml of deionized
water (pH 8).

The third fraction was collected and

lyophilized.

The freeze-dried fraction was re-dissolved in

250 ul water.

50 ul of aliquots were stored at –800C until

it was analyzed for ACPs measurement.
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2.2. Bronchoalveolar Lavage Fluid Sample Preparation

The bronchoalveolar lavage fluids were obtained by
pulmonary lavage.

Briefly, rats were lavaged with 2 ml of

the phosphate buffered medium as described above. The
recovered BAL fluid (~ 1 ml) for each rat was centrifuged
at 500 x g for 5 minutes.

The supernatant for each sample

was mixed with an equal volume of 6% sulfosalicylic acid.
The treated fluid was centrifuged at 2000 x g at 4

0

C for 20

min, and loaded into a C18 cartridge (Vac 6, Waters).

The

column was eluted in succession with 15 ml of watersaturated ethyl acetate (pH 2.4), 15 ml of 30% methanol in
water (pH 2.4), and 3 ml of deionized water (pH 8.0).
last fraction was collected and lyophilized.

The

The freeze-

dried fraction was re-dissolved in 100 µl water.

Aliqots of

20 µl samples were stored at –800C until time for analysis.

2.3. Separation of Arginine and Arginine-Containing
Peptides by HPLC

The separation of arginine and arginine-containing
peptides was achieved by using high performance liquid
chromatography (HLPC).

The HPLC system consisted a Waters

600E system controller, Waters WISP 701B autosampler,
Waters 486 tunable absorbance detector, and Waters 746 data
module (Waters Corp., Milford, MA).

The HPLC separation

method was developed by using a C18 reversed-phase column
(Keystone Scientific, 150 x 4.6 mm, 3 um) and a mobile
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phase consisting of 0.1% trifluoroacetic acid (TFA, pH 2.4)
in water as solvent A and 0.1% TFA in CH3CN as solvent B.
The flow rate was 1 ml/min with 90% of solvent A and 10%
solvent B.

Elutes were detected by UV detection at 215 nm.

Commercially available L-arginine, Arg-Gly, and Arg-Gly-Asp
were chosen as standards and Arg-Sar as an internal
standard.

2.4. Quantitative Determination of Arginine and ArginineContaining Peptides

Standard samples for each compound of analysis was
prepared by spiking known concentrations of the compound in
the appropriate fluid, followed by the extraction
procedures described above.

Following HPLC analysis, a

standard curve was generated by plotting the peak area
ratio of compound/internal standard against the
concentration ratio of the compound /internal standard.
Linear regression analysis was made, and the standard curve
was used to determine the concentration of the compound.

2.5. Accuracy and Precision

Plasma samples were repeatedly measured by HPLC
according to the method described above at different times
within a day, or different days.

The samples were kept in

ice (within a day) or frozen at –80

0

C (different days).

Precision values of the within-day (interassay) and
between-day (intraassay) were determined in six replicates
at each concentration of 0.2, 1.0, and 2.0 ug/ul for Arg;
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0.05, 0.1, and 1.0 ug/ul for Arg-Gly; 0.01, 0.1, and 0.2
ug/ul for Arg-Gly-Asp in plasma and bronchoalveolar lavage
fluid.

The mean concentrations and the coefficients of

variation were calculated.

The accuracy of the assay was

determined by comparing the nominal concentrations with the
corresponding concentrations via linear regression.

2.6. Sample Recovery Experiment

A standard curve for the internal standard, Arg-Sar,
was first generated by the plot of a series of Arg-Sar
standard solutions (0.2, 0.5, 1.0, 1.5, and 2.0 mM) against
the corresponded peak area.

Arg-Sar was added into 10 ml

blood sample or 1 ml lavage fluid (20 uM final
concentration).

The sample was then processed as described

in 2.1. or 2.2.

The amount of Arg-Sar recovered from the

plasma or lavage fluid was determined according to the
method described in 2.4.

The recovery rate was calculated

using following formula:
(amount measured / amount added) X 100%

20 uM of arginine and arginine-containing peptides
were added into 10 ml blood or 1 ml lavage fluid,
respectively.

10 ml blood and 1 ml lavage fluid without

arginine and arginine-containing peptides addition were
used as controls.

After following the same procedure as

Arg-Sar described above, the recover ratios for Arg, ArgGly, Arg-Gly-Asp were determined by using a similar method
except for the subtraction of the corresponding amounts of
Arg, Arg-Gly, Arg-Gly-Asp in the blood.
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[(amount measured – amount in control) / amount added] X
100%

2.7. Arginine-Containing Peptides Uptake and Utilization by
Alveolar Macrophages

2.7.1. Isolation of Alveolar Macrophages

Male Sprague-Dawley rats (~ 250 g) were anesthetized
with sodium pentobarbital (0.2 g/kg body weight) and
exsanguinated by cutting the renal artery. Alveolar
macrophages were obtained by pulmonary lavage with a Ca2+,
Mg2+-free phosphate-buffered medium (145 mM NaCl, 5mM KCl,
1.9 mM NaH2PO4, 9.35 mM Na2HPO4, and 5.5 mM glucose, pH 7.4).
Lavaged cells were centrifuged at a 500 x g for 5 minutes,
washed, and resuspended in the same phosphate-buffered
medium. Cell counts and purity was measured using an
electronic cell counter equipped with a cell sizing
attachment (Coulter Electronics, Hialeah, FL).

2.7.2. Intracellular Fluorescence Uptake by Alveolar
Macrophages

Isolated AM were dispersed into 24 well culture plates
at 106 cells/well and was incubated with 5 uM of FITC, Lys*,
β-Ala-Lys*, Arg-Lys*, or Gly-Sar-Lys* with/without 100 uM
inhibitors (lysine and cephradine) in Earle’s salt solution
for 2 hours at final volume of 1 ml.

The uptake was

terminated by discarding the supernatant and adding icecold Earle’s balanced salt solution.
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washed 4 times with ice-cold Earle’s salt solution and were
sonicated (MSE sonicator, Fisher, Pittsburgh, PA) for 15
minutes.

After a 5 minutes centrifugation, the supernatant

was collected and measured for relative fluorescence
intensity at λex = 494 nm, λem = 519 nm.
2.7.3. Utilization of Arginine-Containing Peptides by
Alveolar Macrophages for Nitric Oxide (NO) Production
Isolated AM were cultured at 1x106 AM/ml in argininefree Earle’s salt solution containing 2mM of glutamine and
5% of fetal bovine serum with/without LPS (1ug/ml)(Thomas
et al. 1993).

200uM of arginine or arginine-containing

peptides (Arg-Gly, Arg-Gly-Asp) were added and incubated at
37oC for 24 hours.

The AM-conditioned media were collected.

NO production was determined by measuring the accumulation
of nitrite using Greiss assay (Smith, et al. 1975).

2.7.4. Inhibitory Effects of Anti-Rat PepT1 Antiserums on
NO Production in AM

The cells were co-incubated with different
concentrations of two rabbit anti-rat PepT1 antiserums
(I,II) and arginine-containing peptides.

The inhibitory

effects of inhibitors or antiserums on NO production by
LPS-activated alveolar macrophages were determined
according to the procedure described above.
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2.7.5. Lactate Dehydrogenase (LDH) Determination

Cell viability was determined by measuring the lactate
dehydrogenase (LDH) from release of AM into the
extracellular medium in various AM incubation mixtures
using an automated Cobas FARA II (Rosh, San Francisco, CA).
LDH activity was monitored spectrophotometrically at 340 nm
as it reductated pyruvate and oxidated coupled with the
oxidation of NADH.

2.8. Presence of Peptide Transporter in Alveolar
Macrophages

2.8.1. Sample Preparation

Isolated AM were seeded and cultured with or without
LPS (1 ug/ml) in Earle’s salt culture medium for 24 hours.
Cells were collected, washed with ice-cold PBS buffer, and
centrifuged.

AM were suspended in homogenizing buffer (20%

glycerol, 0.1 M Tris·HCl, and 10 mM EDTA, pH 7.4) containing
various protease inhibitors (1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 1 mM benzamidine, and 100
µg/ml aprotinin).

The cell suspension was homogenized with

a glass tissue grinder and sonicated for 10 second on ice.
Homogenates were then centrifuged at 5,000 x g for 10 min.
and the pellet (the nuclear fraction) was discarded.

The

supernatant fluid was centrifuged at 50,000 x g for 2 hours
and resulting pellet (cell membrane fraction) was
resuspended in homogenizing buffer.

Protein concentration

of the membrane fraction was determined by Lowry’s assay.
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50 ml aliquots of the membrane preparations were stored at
–80 0C.

2.8.2. Western Blot

A membrane fraction containing 80 ug protein was
loaded on 7% of SDS-PAGE and then transferred to a
nitrocellulose membrane.

The membrane was incubated for 1

hour with polyclonal rabbit antibodies specific to rat
PepT1.

After washing, the blot was incubated sequentially

with secondary antibody labeled with horseradish
peroxidase-conjugated goat anti-rabbit IgG (Pierce,
Rockford, IL) and detected by enhanced chemiluminescence.
The signal densities of the protein bands were measured
using a Fluochem 8000 densitometer (Alpha Innotech Corp.,
Alexandria, VA).

2.9. Substrate Specificity Studies

2.9.1. Utilization of Arginine-Containing Peptides by iNOS
in vitro for NO Production

Arginine-containing peptides were incubated with iNOS
and NO production measured using a modified method of
Stuehr et al. (1992).

Briefly, 0.1mg of iNOS was incubated

with 200 uM of arginine, arginine-containing peptides (ArgGly, Arg-Gly-Asp), 4 uM of H4biopterin, 4 uM of FAD, 3mM of
dithiothreitol (DTT), 2mM of NADPH, and 40 mM of Tris HCl
buffer (pH 7.9 total volume of 1 ml).
determined by Greiss assay.

NO production was

The production of NO by
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arginine-containing peptides was compared with that by
arginine.

2.9.2. Enzyme Kinetic Studies of Arginine-Containing
Peptides for NO Production

Arginine, and arginine-containing peptides including
Arg-Gly and Arg-Gly-Asp at the concentration of 15, 20, 30,
60, 120,180, 240uM were incubated with iNOS, and Km and
Vmax were determined using the Michaelis-Menten equation.
For inhibition studies, NG-monomethyl-L-arginine (L-NMMA)
was added to the reaction mixtures at concentration of 0,
1, 4, 8, 12, 16, 20, 24, and 28 uM.

The IC50 was calculated

by using the Winnonlin Nonlinear Estimation Program
(V03.0A).

3. Statistical Analysis
Data are presented as mean ± standard deviations of at
lease six measurements from different animals in all
experiments.

Statistical analysis was conducted using a

one-way analysis of variance (ANOVA) with a Tukey multiple
comparison procedure with significance set at p< 0.05.
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1. Separation of arginine and arginine-containing peptides
by HPLC

Arg-Gly and Arg-Gly-Asp are chosen as representative
of the arginine-containing di-and tri-peptides.

Arg-Sar,

which contains the N-monomethylglycine residue, is not
found in biological samples.

Due to its structural

similarity to ACPs, stable and resistant to peptidase
degradation, Arg-Sar was chosen as internal standard for
the HPLC quantitative assay.

Chromatographs of base line separation of arginine
(Arg, R), arginine-containing peptides (Arg-Gly, RG; ArgGly-Asp, RGD), and internal standard (Arg-Sar, RS) were
shown in Figure 4.

The retention time was 5.8 min (Arg),

7.5 min (Arg-Gly), 12.6 min (Arg-Gly-Asp), and 16.8 min
(Arg-Sar) in rat plasma, respectively.

The similar results

were in rat BAL fluid (Figure 5).

2. Standard Curves

Standard curves were generated for arginine or
arginine-containing peptides by plotting the peak area
ratio of compound/internal standard against the
concentration ratio of the compound /internal standard.
The standard curves were obtained in the concentration
range of 0.2 – 2.0 µg/µl for Arg, 0.05 – 1.0 µg/µl for Arg30
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Gly, and 0.01 – 0.2 µg/µl.

The limit of quantitation (LOQ)

was set at 0.2 µg/µl for Arg, 0.05 µg/µl for Arg-Gly, and
0.01 µg/µl for Arg-Gly-Asp in both plasma and BAL fluid.
3. Sample Recovery Experiment

six samples of plasma and lavage fluid, with or
without the addition of standard arginine and argininecontaining peptides, were processed and analyzed as
described in the method section.

Recovery rates of Arg,

and arginine-containing peptides from rat plasma and BAL
fluid were calculated and shown in table I.

Table I shows the % recovery of arginine and the
peptides in plasma and in BAL fluid samples for the
developed HPLC method.

The sample preparation procedure

resulted in a ~15 % loss of added concentration in plasma
and less then 10 % loss of concentrations in BAL fluid.
These results are within acceptable ranges for biological
samples.

In addition, the recovery rate for all testing

compounds is about the same, suggesting that this method
should be very consistent for the analysis of the
individual and relative quantities of arginine and the
arginine-containing peptides.

4. Accuracy and Precision

The accuracy and precision for quantitative assay of
Arg and ACPs from plasma and BAL fluid were processed as
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described in method section and the results were shown in
Table II-IV.

The within-day precision expressed as the coefficients
of variation (% C.V.).

As shown in these tables, in

plasam, the values for Arg ranged from 7.9 to 11.8%.
Arg-Gly, the value ranged from 7.9 to 13.

For

For Arg-Gly-Asp,

the value ranged from 4.3 to 14.1.

The accuracy of the assay in plasma varied in the
range from 99.4 to 105.2% for Arg; from 102.5 to 104 for
Arg-Gly; and from 101.3 to 102.2% for Arg-Gly-Asp.

The similar CV % and accuracy results were obtained in
BAL fluids.

CV% value for Arg ranged from 8.3 to 11.4%;

for Arg-Gly from 5.2 to 11.3%; for Arg-Gly-Asp from 5.7 to
11.6 (table not shown).

For accuracy, Arg from 99.1 to

100.8%; Arg-Gly from 98.9 to 100.4%; and Arg-Gly-Asp from
100.1 to 101.3%.

According to FDA “Specific Recommendation for Method
Validation”, the acceptance criteria are not more than 15%
CV for precision and not more than 15% deviation for the
nominal value for accuracy.

The method for quantitative

assay for Arg and ACPs reached the FDA requirement,
suggesting the HPLC method for quantitative assay for Arg
and ACPs are reliable.
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5. Determination of Arginine and Arginine-Containing
Peptides in Plasma and Bronchoalveolar Lavage Fluid.

The concentrations of arginine and arginine-containing
peptides in plasma and bronchoalveolar lavage fluid are
shown in table V.

The concentration of arginine in rat

plasma was 81 uM, which is similar to that previously
reported by Barbul (1990).

The plasma concentration of

Arg-Gly, and Arg-Gly-Asp was 19.7 uM and 8.8 um,
respectively.

These results demonstrate for the first time

the presence of arginine-containing peptides in rat plasma.

Considering the possible different combinations of
arginine and other amino acids, the total concentration of
arginine-containing peptides in plasma is high.

This

suggests that such as a large quantity of argininecontaining peptides may be utilized by different tissues.
Notably, the similarly high concentration of argininecontaining peptides in bronchoalveolar lavage fluid
suggests that these small peptides may also be directly
utilized by the lung tissues.

6. Intracellular Fluorescence Uptake by AM

To test the whether the small peptides can be directly
utilized by the lung, the uptake of fluorescently
conjugated peptides by AM was compared to that of
fluorescently conjugated amino acid and fluorescent probe
(FITC) only.

As shown in Fig 3, the uptake of FITC by AM

was minimal.

In contrast FITC-labeled Lys (Lys*) and small
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peptides (β-Ala-Lys*, Arg-Lys*, and Gly-Sar-Lys*) showed
enhanced intracellular accumulation, suggesting active
transport-mediated uptake of the compounds.

The uptake of

Lys* by AM was completely blocked by non-labeled lysine but
was not inhibited by cephradine, a reported substrate for
PepT1 transporter.

The uptake of the small peptides was

consistently inhibited by cephradine but not by lysine.
These results suggested that the small peptides were
transported through a membrane transporter that is
different from the lysine transporter, and were
internalized by AM without prior degradation.

7. Utilization of Arginine-Containing Peptides by Alveolar
Macrophages for Nitric Oxide (NO) Production

To determine if AM can directly utilize the small
peptides for NO production, NO production of these peptides
in LPS-activated AM was measured and compared with that by
arginine.

Table VI shows the production of NO by non-

stimulated and LPS-stimulated AM in the presence of 200 µM
arginine or arginine-containing di- and tri-peptides.
While both arginine and the small peptides were utilized by
AM to produce NO, the production of nitrite through the
peptides was consistently higher (~ 2-fold) than that of
the arginine system, in LPS-primed cells.

Figure 7 shows the effect of various inhibitors of membrane
transport on NO production in LPS-stimulated AM.
Lysophosphatidylcholine (LPC) has been identified as a
potent inhibitor of CAT-2B-mediated amino acid transport.
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Our results showed that LPC at 5 µM, significantly inhibited
NO production through arginine but had little or no effect
on AM production of NO through arginine-containing
peptides.

In addition, lysine (1 mM) markedly inhibited NO

generation through the arginine system, but failed to block
NO production generated through Arg-Gly or Arg-Gly-Asp.
Interestingly, lysine also blocked AM production of NO
through the use of Arg-Lys as a substrate.

This was not

expected, but presumably due to the fact that both the
arginine and lysine moieties are cationic, thus allowing
this small peptide to be transported by both the amino acid
and peptide transporters.

Figure 2 further shows that the

PepT1 inhibitors, cephalexin and cephradine, selectively
inhibited NO production through the arginine-containing
peptides, but had little effect on the arginine system.

The above results clearly show that LPS-induced iNOS
activity in AM for NO synthesis is largely dependent upon
the transport or uptake of the substrate(s).

While

arginine is transported through CAT-2B, the argininecontaining peptides are internalized through a peptide
transporter. This finding is different from that of an
earlier study on chicken macrophages, which suggested that
arginine-containing dipeptides were hydrolyzed to produce
arginine before cellular uptake (Su and Austic, 1998).

The

fact that these peptides resulted in increased production
of NO, 2-fold to that produced through arginine, suggests
that these small peptides are more efficiently taken up by
the cells or they may serve as direct and better substrates
for iNOS.
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8. Inhibitory Effects of Anti-Rat PepT1 Antiserums on
Utilization of Arginine-Containing Peptides for NO
Production in AM

A number of transporters including PepT1 and PepT2
have been identified for di- and tri-peptide transport (Fei
et al., 1994; Saito et al., 1996).

It is reasonable to

suggest that in various organ systems, where transport or
absorption of small peptides is necessary, there are
similar peptide transporters.

In the lung, it is already

reported that peptide transporter(s) is present in Type II
cells, the broncho epithelium, and the small vessel
endothelium (Groneberg et al., 2001).

We hypothesize that

a PepT1-like transporter is responsible for the uptake of
arginine-containing di- and tri-peptides in AM.

For this

reason, two peptide segments of the extracellular domain of
rat pepT1 were chosen for antibody production.

These

peptide segments represent regions of the extracellular
domain that have the highest degree of amino acid sequence
homologous among rat, rabbit, and human PepT1 proteins,
which makes it possible that these regions may be involved
in the binding of small peptides.

Figure 8 shows the

effects of anti-pepT1 anti-serum I and anti-pepT1 antiserum II on NO production by LPS-stimulated AM using
arginine or arginine-containing peptides as a substrate.
Anti-serum I had no effect on NO synthesis in any of the
systems.

But the production of NO was significantly

blocked by anti-serum II.

Neither antibody affected the NO

production using arginine as the substrate.
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effect of antipepT1 antiserum II on AM utilization of
arginine-containing peptides for NO production was dosedependent (Figure 9).

In comparison, antiserum I in the

same concentration range did not inhibit the production of
NO by AM (Figure 10).

It is interesting to point out that

the inhibitory effect of anti-serum II on Arg-lys is
considerably weaker than its inhibition on other peptides.
This again suggests that Arg-lys may be transported through
both the peptide and the cationic amino acid transporters.

Antiserum II is derived from the peptide segment of
pepT1 that contains more charged amino acid residues than
peptide I, the corresponding peptide segment for antiserum
I.

This makes peptide II a more likely segment to be

involved in the proton-coupled small peptide transport
process.

The fact that antiserum II inhibits AM

utilization of the arginine-containing peptides indicate
that AM indeed exhibit a pepT1-like transporter, and that
antiserum II was able to bind and inactivate the
extracellular binding site of the transporter that is
crucial to the peptide transport process.

9. Lactate Dehydrogenase (LDH) Determination

The LDH level was determined in control groups
(without LPS stimulation or any compounds added) and
treatment groups (stimulated with LPS or compounds added).
No statistically significant difference between the two
groups was found, suggesting that no significant cytotoxic
effects occurred during experiments.
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10. Detection of PepT1-like Transporter Protein in Cell
Membrane of AM

Figure 11 shows the Western blotting analysis of the
presence of a PepT1-like transporter protein in the cell
membrane of AM.

In compared to the purified rat PepT1

protein, a 120 kD band, was detected in the membrane
fraction of both LPS-activated and non-activated AM, using
antiserum II.

This protein band was not observed in

antiserum I-treated membrane fractions, suggesting that the
corresponding peptide I segment is probably not present in
the peptide transporter in alveolar macrophages.

Interestingly, when the amino acid sequences of
peptide I (P457-471) and peptide II (P480-494) from rat
pepT1 are compared to those of rat pepT2, there is only 13
% homology for peptide I, but 50 % for peptide II.

This

supports our data that peptide II is involved in the
process of small peptide transport.

The density of the

protein band from LPS-activated AM was significantly higher
(by 2.3-folds) than that of the non-activated AM,
suggesting that LPS, which is known to induce iNOS, also
enhance AM uptake of small peptides through the pepT1-like
transporter.

These results further confirm the presence of

PepT1-like transporter in AM and suggest a role for AM in
regulating lung peptide homeostasis.
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11. Substrate Specificity Studies

Arginine-containing peptides were incubated with iNOS
in vitro to investigate whether the small peptides can be
used as direct substrates for iNOS in NO production.

The

results show that these compounds can be used as direct
substrates for NO production and that these peptides or
amino acid produced a similar amount of NO at certain time
(Fig 9, 10, 11).

Kinetic studies showed that Arginine and

arginine-containing peptides shared similar Km and Vmax
(Fig 12; Table IV), suggesting that the efficiency for NO
production is similar among these compounds.

The NO

production can be blocked by NG-monomethyl-L-arginine (LNMMA) with a similar IC50 value (Table VII).

This finding

suggested that these compounds might share a similar active
site of iNOS.

This result appeared to be contradictory to the
observation that arginine-containing peptides resulted in
more NO production by AM than using arginine as a
substrate.

One possible explanation is that the CAT-2B

transporter, which transports cationic amino acids, may be
blocked by biological compounds such as other amino acids,
LPC, etc, whereas the PepT1-like transporter in the
membrane of AM is more selective in transporting peptide
molecules.
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P457-471

P480-494

NH2

CO
COOH

+++

+++
Peptide I (P457-471): PGHRHTLLVWGPNLY
+ -+ +
Peptide II (P480-494): QKPEKGENGIRFVST

_ _
+ +

Figure 1. Structure of PepT1 (Fei et al., 1994) and
location of two chosen peptide segments for anti-PepT1
antibody development.
PepT1 protein has 12 transcellular domains. Both Nterminal and C-terminal locate intracellularly. It has a
big extracellular loop which is believed as a important
part for its transport functioning. Two peptide segments
(peptide I and peptide II) were chosen from the loop for
the development of anti-PepT1 antibody development.
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MGMSKSLSCFGYPLSIFFIVVNEFCERFSYYGMRALLILYFRNFIGWDDNL
1
STVIYHTFVALCYLTPILGALIADAWLGKFKTIVWLSIVYTIGQAVTSLSSV
2
3
NELTDNNHDGTPDSLPVHVAVCMIGLLLIALGTGGIKPCVSAFGGDQFEEG
4
QEKQRNRFFSIFYLAINAGSLLSTIITPMVRVQQCGIHVKQACYPLAFGIPAI
5
LMAVSLIVFIIGSGMYKKFKPQGNILSKVVKCICFAIKNRFRHRSKQFPKRA
6
HWLDWAKEKYDERLIAQIKMVTRVLFLYIPLPMFWALFDQQGSRWTLQA
7
TTMSGRIGILEIQPDQMQTVNTILIIILVPIMDAVVYPLIAKCGLNFTSLKKM
8
TIGMFLSAMAFVAAAILQVEIDKTLPVFPKANEVQIKVLNVGSENMIISLPG
9
QTVTLNQMSQTNEFMTFNEDTLTSINITSGSQVTMITPSLEPGHRHTLLV
WGPNLYRVVNDGLTQKPEKGENGIRFVSTYSQPINVTMSGKVYEHIASY
NASEYQFFTSGVKGFTVSSAGISEQCDFESPYLEFGSAYTYLITSQATGCPQ
VTEFEDIPPNTMNMAWQIPQYFLITSGEVVFSITGLEFSYSQAPSNMKSVL
10
QAGWLLTVAVGNIIVLIVAGAGQINKQWAEYILFAALLLVVCVIFAIMARF
11
12
YTYVNPAEIEAQFEEDEKKKNPEKNDLYPSLAPVSQTQ

Figure 2. Amino acid sequence of PepT1 in rat intestinal
epithelial cell (Miyamoto et al., 1996).
The numbers of 1 - 12 represent 12 transcellular
domains. The extracellular loop is shown as black color
and the peptide I and II is shown as red color.
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Peptide I segment
Rat:
Rabbit :
Human:

PGHRHTLLVWGPNLY
A**Q***A*****N*
Q**Q***A*****H*
Peptide II segment

Rat:
Rabbit :
Human:

QKPEKGENGIRFVST
**SD*********N*
*************N*

Figure 3. Comparison of amino acid sequence identity of
peptide I and peptide II segments chosen as anti-pepT1
antibody development in different species.
Peptide I segment shares 73% of amino acid identities
among rat, rabbit, and human, respectively. In comparison
to peptide I, peptide II not only shares higher identity
(80%) between rat and rabbit but also shares the highest
identity between rat and human (93%).
* represents the identical amino acid.
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R

RGD
RG

RS

Figure 4. Chromatogram of HPLC Separation of Arginine and
Arginine-Containing Peptides in Plasma Sample.

The elutes

were Arg (R), Arg-Gly (RG), Arg-Gly-Asp (RGD), and Arg-Sar
(RS).
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R

RGD
RG

RS

Figure 5. Chromatogram of HPLC Separation of Arginine
and Arginine-Containing Peptides in Bronchoalveolar lavage
fluid Sample. The elutes were Arg (R), Arg-Gly (RG), ArgGly-Asp (RGD), and Arg-Sar (RS).
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Table I. Recovery Rate of Arginine and ArginineContaining Peptides from Blood and Bronchoalveolar
Lavage Fluid

Recovery rate (%)
Blood

Lavage Fluid

Arg

83.74 ± 1.24

90.32 ± 2.34

Arg-Gly

86.65 ± 2.34

91.46 ± 1.86

Arg-Gly-Asp

87.32 ± 2.06

90.47 ± 2.41

N=5, data are expressed as Mean ± standard deviation
(SD).
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Table II. Evaluation of accuracy and precision for the assay
of arginine in plasma sample

Arginine (µg/µl)
0.2

1.0

2.0

Average ± S.D.
C.V. (%)
Accuracy

0.20
0.22
0.185
0.171
0.20
0.21
0.20 ± 0.02
11.8
101.1

1.08
0.99
1.16
1.10
0.96
0.94
1.04 ± 0.09
8.4
105.2

2.13
2.00
1.89
1.96
2.21
1.78
2.00 ± 0.16
7.9
99.4

Between-day
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Average ± S.D.
C.V. (%)

0.23
0.197
0.188
0.25
0.21
0.22
0.22 ± 0.02
10.5

0.87
1.03
1.12
0.99
0.97
1.05
1.00 ± 0.08
8.4

2.16
2.04
1.97
1.85
2.00
2.07
2.01 ± 0.10
5.2

Within-day
Calculated
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Table III. Evaluation of accuracy and precision for the assay
of Arg-Gly in plasma sample

Arg-Gly (µg/µl)
0.05

0.1

1.0

Average ± S.D.
C.V. (%)
Accuracy

0.05
0.046
0.060
0.061
0.063
0.05
0.055 ± 0.01
13.0
103

0.13
0.12
0.09
0.11
0.12
0.118
0.11 ± 0.01
11.9
102.5

0.98
1.07
1.03
0.89
1.12
1.06
1.02 ± 0.08
7.9
104

Between-day
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Average ± S.D.
C.V. (%)

0.047
0.05
0.064
0.046
0.052
0.061
0.05 ± 0.01
14.0

0.086
0.09
0.12
0.11
0.10
0.97
0.10 ± 0.01
12.6

0.98
1.05
1.11
1.00
0.99
1.07
1.03 ± 0.05
5.0

Within-day
Calculated
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Table IV. Evaluation of accuracy and precision for the assay
of Arg-Gly-Asp in plasma sample
Arg-Gly-Asp (µg/µl)
0.01

0.1

0.2

Average ± S.D.
C.V. (%)
Accuracy

0.01
0.012
0.013
0.01
0.009
0.01
0.01 ± 0.01
14.1
101.3

0.09
0.12
0.113
0.09
0.12
0.118
0.11 ± 0.01
13.4
102.2

0.21
0.20
0.196
0.206
0.189
0.19
0.20 ± 0.01
4.3
101.4

Between-day
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Average ± S.D.
C.V. (%)

0.047
0.05
0.064
0.046
0.052
0.061
0.05 ± 0.01
14.0

0.11
0.12
0.09
0.08
0.10
0.09
0.10 ± 0.02
15.0

0.19
0.23
0.18
0.20
0.19
0.18
0.20 ± 0.02
9.6

Within-day
Calculated
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Table V. Concentrations of Arginine and ArginineContaining Peptides in rat Plasma and Bronchoalveolar
Lavage Fluid.

Concentration (uM)
Blood
BAL Fluid
Arg

81.45 ± 3.28

82.61 ± 4.16

Arg-Gly

19.65 ± 2.41

11.37 ± 2.46

8.77 ± 1.03

7.62 ± 1.61

Arg-Gly-Asp

N=6, data are expressed as Mean ± standard deviation
(SD).
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100
80
60

*

40

Lys

*

*

20
0

Control

FITC*

Lys*

Arg-Lys*

B-Ala-Lys*

*

Cephradine

Gly-Sar-Lys*

Figure 6. Transporter-mediated uptake of 5 µM FITClabeled lysine (Lys*) and small peptides (Arg-Lys*,
β-Ala-Lys*, Gly-Sar-Lys*) by alveolar macrophages
(106 Cells). Lys (1 mM) and cephradine (1mM) was
used as inhibitors for CAT-2B and PepT1 transporters,
respectively. * Significant difference from control
at P < 0.05, n = 6.
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Table VI. Production of NO by non-stimulated and LPSstimulated AM in the presence of arginine and argininecontaining peptides

Nitrite (µM)
Substrate

-LPS

+LPS

Cells only

1.4 ± 0.2

2.5 ± 0.3

Arg

2.1 ± 0.4

21.5 ± 3.5

Arg-Lys

7.2 ± 1.3

39.2 ± 5.1*

Arg-Gly

5.1 ± 0.3

41.9 ± 3.6*

Arg-Gly-Asp

3.7 ± 1.0

38.4 ± 2.1*

At equal molar concentration (200uM) of Arg and ACPs, NO
production from 106 AM with/without LPS stimulation was
measured following 24-hour incubation and expressed as
nitrite (uM). Each value represents the mean ± SD of six
separation experiments.
* indicates significant difference from AM + Arg, p < 0.05
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50
45
40
35
30
25
20
15
10
5
0

Control
LPC
Lys
Cephalexin
Cephradine

*
*
*
*
Arg

*

*
Arg-Lys

Arg-Gly

*

*
*

Arg-Gly-Asp

Figure 7. Inhibitory effects of CAT and PepT1 transporter
inhibitors on NO production by LPS-stimulated AM. 1mM of
Lys, cephradine, and cephalexin; 5uM of LPC were used as
inhibitors. * indicates significant difference from control
at P < 0.05; n = 6.
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50
Nitrite (uM)

40

*

30

*

20

Control
Antiserum I
Antiserum II

10
0
Arg

Arg-Lys

Arg-Gly

Arg-Gly-Asp

Figure 8. Effects of anti-PepT1 antiserum I (1:10) and
anti-PepT1 antiserum II (1:10) on AM production of NO
using arginine and arginine-containing peptides as
substrates.
* indicates significant difference from the control
(Arg). P < 0.05, n = 6.
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50

Nitrite (uM)

40

*

30

*
*

*
*

20

*

Control
Antiserum II (1:100)
Antiserum II (1:20)
Antiserum II (1:10)
Antiserum II (1:2)

10
0

Arg

Arg-Lys

Arg-Gly

Arg-Gly-Asp

Figure 9. The dose-dependent effects of anti-PepT1
antiserum II on NO production by LPS-stimulated AM using
arginine or arginine-containing peptides as the substrates.
The antiserum dilutions were 1:100, 1:20, 1:10, 1:2.
Antiserum II significantly block the NO production by ArgLys, Arg-Gly-Asp in a dose dependent manner. N=6, P < 0.05.
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50

Nitrite (uM)

40
Control
Antiserum I (1:100)
Antiserum I (1:20)
Antiserum I (1:10)
Antiserum I (1:2)

30
20
10
0
Arg

Arg-Lys

Arg-Gly

Arg-Gly-Asp

Figure 10. The dose-dependent effects of anti-PepT1
antiserum I on NO production by LPS-stimulated AM using
arginine or ACPs as the substrates. The antiserum
dilutions were 1:100, 1:20, 1:10, 1:2. N=6, P < 0.05.
Unlike to the antiserum II, no dose-dependent effects of
the antiserum I on NO production by LPS-stimulated AM were
observed.
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A

B

C

D

E
80000

212 kD
Signal Desity

70000

116 kD
97 kD
66 kD

60000
50000
40000
30000
20000
10000

39.2kD

0
C

D

E

Figure 11. Western Blot of PepT1-like Transporter on the
membrane fraction of AM.
A 120 kD bands were detected in membrane fraction of
both LPS-stimulated and non-stimulated AM using antiPepT1 antiserum II. Western Blot of AM membrane proteins
using anti-p480-494 antiserum (antiserum II).

The signal

densities of corresponding bands were measured.
A: Molecular weight marker;
PepT1 standard protein;

B: Preimmune serum;

D: LPS-stimulated AM;

stimulated AM.

56

C:

E: Non-

Vo(NO umol/mgprotein/min)

Chapter IV Results and Discussion

7
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1
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100

200

300

Arginine (uM)

Figure 12. Michaelis-Menten Saturation Curve of Arginine.
n = 5. The Kinetics was carried out by incubation of 0.1
mg iNOS with arginine as substrates at concentration of 15,
20, 30, 60, 120, 180, and 240 µM for 4 min. The initial
rates of NO synthesis were measured spectrophotometrically
using the Greiss assay.
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Figure 13. Michaelis-Menten Saturation Curve of Arg-Gly.
n = 6. The Kinetics was carried out by incubation of 0.1
mg iNOS with Arg-Gly as substrates at concentration of 15,
20, 30, 60, 120, 180, and 240 µM for 4 min. The initial
rates of NO synthesis were measured spectrophotometrically
using the Greiss assay.
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1.0
0.0
0

100

200

300

Arg-Glt-Asp (uM)

Figure 14. Michaelis-Menten Saturation Curve of Arg-GlyAsp.
n = 5. The Kinetics was carried out by incubation of 0.1
mg iNOS with Arg-Gly-Asp as substrates at concentration of
15, 20, 30, 60, 120, 180, and 240 µM for 4 min. The
initial rates of NO synthesis were measured
spectrophotometrically using the Greiss assay.
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0.8

0.6

Arg
Arg-Gly
Arg-Gly-Asp

0.4

0.2

0.0
-0.04

-0.02

0.00

0.02
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0.06
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Figure 15. Lineweaver-Burk plots for iNOS activity using
Arg, Arg-Gly, and Arg-Gly-Asp as substrate (n=5).
The enzyme reactions were carried out by incubation
0.1 mg iNOS with arginine or arginine-containing peptides
at concentrations of 15, 20, 30, 60, 120, 180, and 240 µM
for 4 min. The initial rates of NO synthesis were measured
spectrophotometrically using the Greiss assay.
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Table VII. Km, Vmax, and IC50 values for the enzyme kinetics
of iNOS using Arg, Arg-Gly, and Arg-Gly-Asp as substrates
and L-NMMA as a competitive NO inhibitor.

Substrate

Vmax

Km
(µ
µM)

(µ
µmol/min/mg protein)

IC50 (L-NMMA)
(µ
µM)

Arg

59.3 ± 2.1

6.6 ± 0.7

14.2 ± 1.1

Arg-Gly

56.0 ± 1.8

8.4 ± 1.2

12.8 ± 0.8

Arg-Gly-Asp

60.1 ± 2.2

6.8 ± 1.3

14.0 ± 0.6

Each value represents the mean ± SD of six separation
experiments.
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Chapter V
Summary and Conclusion

A HPLC method to analyze arginine and argininecontaining peptides from blood and bronchoalveolar lavage
fluid has been established.

The accuracy and precision of

assay is within 15% deviation and 15% C.V., respectively,
which reach the FDA requirement for analytical method
validation guide.

The limit of quantitation (LOQ) was in

nano-range without derivatization, 0.2 µg/µl for Arginine,
0.05 µg/µl for Arg-Gly, and 0.01 µg/µl for Arg-Gly-Asp in
both plasma and BAL fluid. So the method is simple,
accuracy and reliable.

This project also demonstrates that argininecontaining di- and tri-peptides are direct substrates to
the inducible nitric oxide synthase.

Arginine-containing

peptides such as Arg-Gly and Arg-Gly-Asp, which are present
in significant concentrations in plasma and the lungs, can
be readily internalized through a peptide transport process
and utilized for NO synthesis by a variety of cell types.
This notion is in agreement with several reports that many
di- and tri-peptides in plasma are directly absorbed by
various organs without hydrolytic degradation (Lochs et
al., 1988; Fei et al., 1994).

In the pulmonary system,

where NO production on one hand protects the lung from
bacteria infection (Boockvar et al., 1994) and on the other
hand exacerbates inflammatory lung injury, AM are shown to
exhibit PepT1-like transporter and produce high levels of
NO by directly using arginine-containing peptides as
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substrates. This study suggests a plausible mechanism
through which a significant portion of the NO production by
AM may be generated.

The transport and utilization of arginine-containing
peptides by AM may have a broader implication on the
regulatory role of peptide transporters in various
biological systems.

Studies have shown that renal-impaired

patients may develop hypertension due to reduced production
of NO by endothelial cells.

The reason for the reduction

of NO synthesis has been attributed to a blockage of
arginine transport through the CAT-2B transporter by
compounds such as LPC, a natural CAT-2B inhibitor (Kikuta
et al., 1998; Caivano, 1998).

Our studies showed that LPC

indeed blocked AM production of NO through arginine uptake
but had no effect on the cellular uptake and utilization of
the arginine-containing peptides.

This suggests that

arginine-containing peptides, which are internalized
through a peptide transporter, may be considered as an
alternative source of substrates for NO synthesis.
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